Fresh Tracks Therapeutics Inc Investor Relations Material
Latest events
Q3 2022
Fresh Tracks Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Fresh Tracks Therapeutics Inc
Access all reports
Fresh Tracks Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. It develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases. The company has license agreements with Carna Biosciences Ltd., Voronoi Inc., Bodor Laboratories Inc., Dr. Nicholas S. Bodor and AnGes, Inc.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States